The drug discovery engine of Allorion integrates technological breakthroughs in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors of well-validated targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/24/21 | $40,000,000 | Series A |
Elikon Venture Firstred Capital IDG Capital Partners Med-Fine Capital Octagon Capital Qiming Venture Partners  TF Capital | undisclosed |
